Aktienanalyse zu Taysha Gene Therapies Inc (TSHA)TSHATaysha Gene Therapies Inc

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Taysha Gene Therapies Inc is a good buy right now due to its current price of $5.77 being significantly lower than analyst price targets ranging from $10 to $15, indicating potential upside of 73% to 160%. Additionally, the company has a strong cash position of $276.6 million, which can fund operations into 2028, providing financial stability despite recent insider selling. However, the main risk is the negative earnings trend, with a net loss of $46.6 million reported in Q2 2026.